This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.
Program Description
For patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), treatment has been proven with intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies. In 2019, nearly 7 million anti-VEGF injections were performed in the United States for patients with these conditions, contributing to significant burden for patients, caregivers, and the health care system. Specialty and managed care pharmacists can make important interventions for patients with nAMD and DME by incorporating new and emerging treatment options into formularies. This activity will review considerations for current treatment options, emerging dual-targeted therapy with the angiopoietin (Ang) pathway, and the potential role of new medication delivery systems for patients with nAMD or DME. The pharmacist’s role in combating nonadherence and reducing health care resource utilization for patients with nAMD and DME will also be examined.
Target audience: Specialty pharmacists and managed care pharmacists
Type of activity: Application
Release date: August 30, 2022
Expiration date: October 30, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the current treatment options for neovascular age-related macular degeneration and diabetic macular edema
- Analyze the latest efficacy and safety data for emerging therapies and treatment approaches for neovascular age-related macular degeneration and diabetic macular edema
- Demonstrate the role of specialty pharmacists and managed care professionals in the management of neovascular age-related macular degeneration and diabetic macular edema
